Pfizer Inc. (NYSE:PFE) Stock Holdings Lessened by Archer Investment Corp

Archer Investment Corp decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 62,519 shares of the biopharmaceutical company’s stock after selling 6,484 shares during the quarter. Archer Investment Corp’s holdings in Pfizer were worth $1,809,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the business. China Universal Asset Management Co. Ltd. bought a new stake in shares of Pfizer in the 1st quarter valued at $315,000. Dorsey & Whitney Trust CO LLC grew its holdings in shares of Pfizer by 16.0% in the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 72,467 shares of the biopharmaceutical company’s stock valued at $2,011,000 after acquiring an additional 9,989 shares in the last quarter. Forum Financial Management LP grew its holdings in shares of Pfizer by 1.8% in the 1st quarter. Forum Financial Management LP now owns 57,342 shares of the biopharmaceutical company’s stock valued at $1,591,000 after acquiring an additional 1,033 shares in the last quarter. M&G Plc acquired a new stake in Pfizer in the 1st quarter valued at about $19,885,000. Finally, Poehling Capital Management INC. lifted its stake in Pfizer by 9.3% in the 1st quarter. Poehling Capital Management INC. now owns 54,416 shares of the biopharmaceutical company’s stock valued at $1,510,000 after purchasing an additional 4,609 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE stock traded down $1.33 during trading hours on Friday, hitting $24.69. The stock had a trading volume of 7,016,707 shares, compared to its average volume of 37,672,426. The firm has a market capitalization of $139.92 billion, a PE ratio of 33.37, a PEG ratio of 0.85 and a beta of 0.67. Pfizer Inc. has a twelve month low of $24.65 and a twelve month high of $31.54. The stock’s 50 day moving average is $28.71 and its 200 day moving average is $28.65. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter in the prior year, the business posted ($0.17) earnings per share. Pfizer’s revenue was up 31.2% compared to the same quarter last year. As a group, research analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.80%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio is currently 227.03%.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. StockNews.com raised shares of Pfizer from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Wells Fargo & Company raised their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Wolfe Research started coverage on shares of Pfizer in a research note on Friday. They issued an “underperform” rating and a $25.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. Finally, Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $32.92.

Insider Activity

In other news, Director Scott Gottlieb acquired 1,000 shares of the business’s stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares in the company, valued at $282,400. This represents a 11.11 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.